MA53009A - Agents inhibiteurs d'ask1 - Google Patents
Agents inhibiteurs d'ask1Info
- Publication number
- MA53009A MA53009A MA053009A MA53009A MA53009A MA 53009 A MA53009 A MA 53009A MA 053009 A MA053009 A MA 053009A MA 53009 A MA53009 A MA 53009A MA 53009 A MA53009 A MA 53009A
- Authority
- MA
- Morocco
- Prior art keywords
- ask1 inhibitors
- ask1
- inhibitors
- Prior art date
Links
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 title 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690674P | 2018-06-27 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53009A true MA53009A (fr) | 2021-05-05 |
Family
ID=67254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053009A MA53009A (fr) | 2018-06-27 | 2019-06-26 | Agents inhibiteurs d'ask1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11814362B2 (fr) |
| EP (1) | EP3814333B1 (fr) |
| JP (1) | JP2021528456A (fr) |
| KR (1) | KR20210024532A (fr) |
| CN (1) | CN112638896A (fr) |
| AR (1) | AR115636A1 (fr) |
| AU (1) | AU2019291806A1 (fr) |
| BR (1) | BR112020026423A2 (fr) |
| CA (1) | CA3104662A1 (fr) |
| CL (1) | CL2020003375A1 (fr) |
| CO (1) | CO2021000782A2 (fr) |
| CR (1) | CR20210049A (fr) |
| EA (1) | EA202190034A1 (fr) |
| ES (1) | ES3032286T3 (fr) |
| IL (1) | IL279709A (fr) |
| JO (1) | JOP20200318A1 (fr) |
| MA (1) | MA53009A (fr) |
| MX (1) | MX2020013895A (fr) |
| PE (1) | PE20211379A1 (fr) |
| SG (1) | SG11202012784SA (fr) |
| TW (1) | TW202035389A (fr) |
| UY (1) | UY38278A (fr) |
| WO (1) | WO2020006031A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64641B1 (sr) | 2018-06-27 | 2023-10-31 | Bristol Myers Squibb Co | Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija |
| CA3104662A1 (fr) | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Agents inhibiteurs d'ask1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| AU2014366235B2 (en) * | 2013-12-20 | 2017-04-13 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2018151830A1 (fr) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
| CA3104662A1 (fr) | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Agents inhibiteurs d'ask1 |
-
2019
- 2019-06-26 CA CA3104662A patent/CA3104662A1/fr not_active Abandoned
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es not_active Application Discontinuation
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko not_active Withdrawn
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 ES ES19739494T patent/ES3032286T3/es active Active
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/fr not_active Ceased
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333B1/fr active Active
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
-
2020
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US12404263B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL279709A (en) | 2021-03-01 |
| SG11202012784SA (en) | 2021-01-28 |
| US20210115020A1 (en) | 2021-04-22 |
| WO2020006031A8 (fr) | 2020-09-24 |
| EP3814333B1 (fr) | 2025-03-19 |
| US12404263B2 (en) | 2025-09-02 |
| EP3814333A1 (fr) | 2021-05-05 |
| CR20210049A (es) | 2021-07-01 |
| AU2019291806A1 (en) | 2021-01-07 |
| JOP20200318A1 (ar) | 2020-12-10 |
| CN112638896A (zh) | 2021-04-09 |
| TW202035389A (zh) | 2020-10-01 |
| WO2020006031A1 (fr) | 2020-01-02 |
| CL2020003375A1 (es) | 2021-09-03 |
| KR20210024532A (ko) | 2021-03-05 |
| US11814362B2 (en) | 2023-11-14 |
| JP2021528456A (ja) | 2021-10-21 |
| PE20211379A1 (es) | 2021-07-27 |
| MX2020013895A (es) | 2021-07-21 |
| BR112020026423A2 (pt) | 2021-03-23 |
| UY38278A (es) | 2020-01-31 |
| CA3104662A1 (fr) | 2020-01-02 |
| AR115636A1 (es) | 2021-02-10 |
| US20240109867A1 (en) | 2024-04-04 |
| CO2021000782A2 (es) | 2021-01-29 |
| EA202190034A1 (ru) | 2021-04-08 |
| ES3032286T3 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| IL283639A (en) | Kif18a inhibitors | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| EP3735685A4 (fr) | Panneau d'affichage | |
| EP3784285C0 (fr) | Agents cryoprotecteurs pour formulations particulaires | |
| EP3843714C0 (fr) | Inhibiteurs de cd73 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP3750149C0 (fr) | Panneau d'affichage | |
| UA42295S (uk) | Комп'ютер | |
| UA42369S (uk) | Комп'ютер | |
| EP3798719A4 (fr) | Panneau d'affichage | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| EP3532240A4 (fr) | Base d'outillage | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
| EP3820980A4 (fr) | Compositions d'esterquats | |
| EP3992176A4 (fr) | Antagoniste d'ep2 | |
| EP3765619A4 (fr) | Inhibiteurs de micro-arn 22 | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| EP3863629A4 (fr) | Promédicaments d'antagonistes du cgrp | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 |